Asthma outcomes: healthcare utilization and costs
- PMID: 22386509
- PMCID: PMC4277846
- DOI: 10.1016/j.jaci.2011.12.984
Asthma outcomes: healthcare utilization and costs
Abstract
Background: Measures of healthcare utilization and indirect impact of asthma morbidity are used to assess clinical interventions and estimate cost.
Objective: National Institutes of Health institutes and other federal agencies convened an expert group to propose standardized measurement, collection, analysis, and reporting of healthcare utilization and cost outcomes in future asthma studies.
Methods: We used comprehensive literature reviews and expert opinion to compile a list of asthma healthcare utilization outcomes that we classified as core (required in future studies), supplemental (used according to study aims and standardized), and emerging (requiring validation and standardization). We also have identified methodology to assign cost to these outcomes. This work was discussed at an National Institutes of Health-organized workshop in March 2010 and finalized in September 2011.
Results: We identified 3 ways to promote comparability across clinical trials for measures of healthcare utilization, resource use, and cost: (1) specify the study perspective (patient, clinician, payer, and society); (2) standardize the measurement period (ideally 12 months); and (3) use standard units to measure healthcare utilization and other asthma-related events.
Conclusions: Large clinical trials and observational studies should collect and report detailed information on healthcare utilization, intervention resources, and indirect impact of asthma, so that costs can be calculated and cost-effectiveness analyses can be conducted across several studies. Additional research is needed to develop standard, validated survey instruments for collection of provider-reported and participant-reported data regarding asthma-related health care.
Published by Mosby, Inc.
Similar articles
-
Asthma outcomes workshop: overview.J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S1-8. doi: 10.1016/j.jaci.2011.12.985. J Allergy Clin Immunol. 2012. PMID: 22386504 Free PMC article.
-
Asthma outcomes: exacerbations.J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S34-48. doi: 10.1016/j.jaci.2011.12.983. J Allergy Clin Immunol. 2012. PMID: 22386508 Free PMC article. Review.
-
Economic impact of severe asthma in Spain: multicentre observational longitudinal study.J Asthma. 2019 Aug;56(8):861-871. doi: 10.1080/02770903.2018.1499035. Epub 2018 Oct 9. J Asthma. 2019. PMID: 30003827
-
Healthcare costs and resource utilization of asthma in Germany: a claims data analysis.Eur J Health Econ. 2016 Mar;17(2):195-201. doi: 10.1007/s10198-015-0671-3. Epub 2015 Feb 26. Eur J Health Econ. 2016. PMID: 25716136 Free PMC article.
-
Asthma outcomes: composite scores of asthma control.J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S24-33. doi: 10.1016/j.jaci.2011.12.980. J Allergy Clin Immunol. 2012. PMID: 22386507 Free PMC article. Review.
Cited by
-
Coordinated Health Care Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO) plan.J Allergy Clin Immunol Glob. 2023 Aug;2(3):100100. doi: 10.1016/j.jacig.2023.100100. J Allergy Clin Immunol Glob. 2023. PMID: 37641662 Free PMC article.
-
Bronchial epithelial cell transcriptional responses to inhaled corticosteroids dictate severe asthmatic outcomes.J Allergy Clin Immunol. 2023 Jun;151(6):1513-1524. doi: 10.1016/j.jaci.2023.01.028. Epub 2023 Feb 14. J Allergy Clin Immunol. 2023. PMID: 36796454 Free PMC article.
-
Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).Eur Respir J. 2023 Apr 3;61(4):2200606. doi: 10.1183/13993003.00606-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 36229046 Free PMC article. Review.
-
Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.Clinicoecon Outcomes Res. 2021 Dec 3;13:957-967. doi: 10.2147/CEOR.S336915. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34887668 Free PMC article.
-
Translational Effect of Provider-Focused, Multi-State, Multi-Clinic Asthma Care Quality Improvement Program on Patient-Level Health Care Costs.J Prim Care Community Health. 2021 Jan-Dec;12:21501327211000246. doi: 10.1177/21501327211000246. J Prim Care Community Health. 2021. PMID: 33749359 Free PMC article.
References
-
- Mattke S, Martorell F, Sharma P, Malveaux F, Lurie N. Quality of care for childhood asthma: estimating impact and implications. Pediatrics. 2009;123(Suppl 3):S199–S204. Epub 2009/04/16. - PubMed
-
- Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. Epub 2009/06/19. - PubMed
-
- Sculpher MJ, Price M. Measuring costs and consequences in economic evaluation in asthma. Respir Med. 2003;97(5):508–520. Epub 2003/05/09. - PubMed
-
- Cannell CF, Marquis KH, Laurent A. A summary of studies of interviewing methodology. Vital Health Stat 2. 1977;i-viii(69):1–78. Epub 1977/01/01. - PubMed
-
- Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007;62(2):126–133. Epub 2007/02/15. - PubMed
